Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer in China.

ABSTRACT:

Objective

The RATIONALE-312 trial demonstrated that the combination of tislelizumab with chemotherapy significantly improved the survival benefits for patients with extensive-stage small cell lung cancer (ES-SCLC). In this study, we used two models to evaluate the cost-effectiveness of tislelizumab in combination with chemotherapy as a first-line treatment for ES-SCLC patients from the perspective of China's healthcare system.

Methods

Based on the RATIONALE-312 trial data, a Markov model and a partitioned survival (PS) model were developed to assess the cost-effectiveness of tislelizumab in combination with chemotherapy as first-line treatment for ES-SCLC. The models set a 3-week cycle length and 10-year time horizon. Cost and utility values were obtained from the drug data

SUBMITTER: Fan X 

PROVIDER: S-EPMC12558940 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature